Poseida Therapeutics, Inc.
(NASDAQ GS: PSTX)
Rigrodsky Law, P.A. is investigating Poseida Therapeutics, Inc. (“Poseida”) regarding possible breaches of fiduciary duties and other violations of law related to Poseida’s agreement to be acquired by Roche Holdings, Inc. Under the terms of the agreement, Poseida shareholders will receive $9.00 per share in cash, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash upon achievement of specific milestones.